Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02519413 · ClinicalTrials.gov registry record
Tecfidera Lymphocyte Chart Review
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 483
- Enrollment target
NCT02519413 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 483 participants.
The verdict
NCT02519413 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 483 participants
- Enrollment target
Study Summary
The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months. The secondary objective is to investigate changes in lymphocyte subtypes other than CD4+ and CD8+ T cells.
Interventions
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 483 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02519413
The ClinicalTrials.gov registry entry for NCT02519413 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 483 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dimethyl fumarate is the first listed.
NCT02519413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02519413 about?
NCT02519413 is a clinical study titled "Tecfidera Lymphocyte Chart Review". The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months. The secondary objective is to investigate changes in lymphocyte subtypes other...
What is the current status of trial NCT02519413?
This trial is currently completed. The enrollment target is 483 participants. The study started on 2015-07. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02519413?
The interventions under investigation include: dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT02519413?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.